Gastric Adenocarcinoma

Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).

PMID 24841718 · Kubota et al., 2014 · Open in CIViC

In the phase 3 GLOW trial (NCT03653507), 507 patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma were randomized 1:1 to receive either zolbetuximab combined with CAPOX … (full text at CIViC)

PMID 37524953 · Shah et al., 2023 · Open in CIViC

In the phase 3 SPOTLIGHT trial (NCT03504397), 565 patients with gastroesophageal junction adenocarcinoma were randomized to receive either zolbetuximab combined with mFOLFOX6 (n=283) or placebo with m… (full text at CIViC)

PMID 37068504 · Shitara et al., 2023 · Open in CIViC

CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resis… (full text at CIViC)

PMID 20651371 · Xie et al., 2010 · Open in CIViC

High DNMT1 expression was found in 105/127 (83%) or patients (by qPCR assay). Low DNMT1 expression was associated with improved histopathological and clinical response and OS in patients with gastric … (full text at CIViC)

PMID 21458988 · Mutze et al., 2011 · Open in CIViC

This retrospective analysis of a Phase 2 trial shows significant association between increased EGFR gene copy number (≥ 4.0) and overall survival (OS) in patients with gastric and oesophago-gastric ju… (full text at CIViC)

PMID 22152101 · Luber et al., 2011 · Open in CIViC

A case report of a 49 year old female with gastric signet ring cell carcinoma, in whom a genomic screen of cf tumour DNA revealed an EGFR::SEPT14 fusion at a VAF of 45.3%. The fusion was confirmed by … (full text at CIViC)

PMID 33969073 · Kim et al., 2021 · Open in CIViC

8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels we… (full text at CIViC)

PMID 23340172 · Nishi et al., 2013 · Open in CIViC

TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer. Primary endpoint was Overall Survival (… (full text at CIViC)

PMID 24868024 · Satoh et al., 2014 · Open in CIViC

ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive (overexpression or amplification) advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and plati… (full text at CIViC)

PMID 20728210 · Bang et al., 2010 · Open in CIViC

ToGA, a Phase III study (NCT01041404) addressed use of trastuzumab in HER2 positive advanced gastric cancer, where chemotherapy using fluoropyrimidine-based and platinum-based combinations had been co…

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to nivolumab-contain… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q was associated with reduced response to oxaliplatin-based regimens compared… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to ramucirumab-conta…

FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.

PMID 26637881 · Schmidt et al., 2015 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

Three FGFR2-amplified gastric cancer cell lines showed submicromolar sensitivity to sorafenib in growth-inhibition assays: HSC-43, HSC-39, and KATOIII had IC50 values of 0.8, 0.6, and 0.4 μM, respecti… (full text at CIViC)

PMID 22890726 · Arao et al., 2013 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear e… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

Cabozantinib's effect on cell proliferation was studied in a variety of cell lines. In two gastric adenocarcinoma cell lines with MET amplification (SNU-5 and Hs746T) were the most sensitive to caboz… (full text at CIViC)

PMID 21926191 · Yakes et al., 2011 · Open in CIViC

A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response … (full text at CIViC)

PMID 22389872 · Catenacci et al., 2011 · Open in CIViC

In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarc… (full text at CIViC)

PMID 28958504 · Catenacci et al., 2017 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.

PMID 22292935 · Shi et al., 2012 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched i… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) … (full text at CIViC)

PMID 25300346 · Zhang et al., 2015 · Open in CIViC

Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC)

PMID 28028034 · Kim et al., 2017 · Open in CIViC

54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser24… (full text at CIViC)

PMID 22343617 · Yoon et al., 2012 · Open in CIViC

The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC)

PMID 28002800 · Xu et al., 2017 · Open in CIViC

In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC)

PMID 24740294 · Xu et al., 2014 · Open in CIViC

In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).

PMID 22422354 · Shen et al., 2012 · Open in CIViC